Drug Type Small molecule drug |
Synonyms YZJ 1139, YZJ-1139 |
Target |
Mechanism OX1R antagonists(Orexin receptor type 1 antagonists), OX2R antagonists(Orexin receptor type 2 antagonists) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
Drug Highest PhasePhase 3 |
First Approval Date- |
RegulationSpecial Review Project (CN) |
Molecular FormulaC25H25FN4O2 |
InChIKeyPMJPLAGTPPVSRL-JLMWRMLUSA-N |
CAS Registry1808918-69-5 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Sleep Initiation and Maintenance Disorders | Phase 3 | CN | 17 Dec 2021 |